MGI Pharma has announced that it will begin the final studies needed for approval of its experimental surgical sedative, Aquavan, early next year.
The company will conduct two late-stage trials starting in early 2006. Both studies will use patients undergoing examinations that use sedation: 300 getting colonscopies in one case and 250 undergoing bronchoscopies in another. The company will also conduct a third safety study using patients undergoing minor surgeries. Enrollment in all three trials should take approximately one year.